NCT00566098 · REGISTRY CONDITION SEARCH

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: COMPLETED
Registry last update: 2023-05-26

RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Hematopoietic Engraftment

→

outcome · POSTED

Disease Response

→

outcome · POSTED

Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation

→

outcome · POSTED

T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)

→

outcome · POSTED

Survival

→

outcome · POSTED

Pneumococcal-specific Vaccine Responses

→

outcome · POSTED

Anti-tumor Immune Responses

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma * Newly diagnosed disease * Durie-Salmon stage II or III disease * Measurable disease, defined by any of the following: * Measurable serum and/or urine M-protein levels documented and available prior to induction therapy * Positive serum free light chain assay * Must have completed a minimum of 3 courses of myeloma specific therapy * Candidate for autologous stem cell transplantation * Patients who have achieved a complete remission at the time of bone marrow harvest for marrow infiltrating lymphocytes (MILs) expansion are not eligible * No evidence of spinal cord compression * Diagnosis of the following cancers are not allowed: * POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) * Non-secretory myeloma (no measurable protein on serum free light chain assay) * Plasma cell leukemia * No amyloidosis PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy ≥ 6 months * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and up to day 180 * Corrected serum calcium \< 11 mg/dL and no evidence of symptomatic hypercalcemia * Total bilirubin ≤ 2.0 times upper limit of normal (ULN) * ALT ≤ 2.0 times ULN * Serum creatinine \< 2.0 mg/dL * No history of other malignancy within the past 5 years, except adequately treated basal cell or squamous cell skin cancer * No history of autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus) requiring systemic treatment * Hypothyroidism without evidence of Graves' disease or Hashimoto thyroiditis is allowed * No infection requiring treatment with antibiotics, antifungal, or antiviral agents within the past 7 days * No HIV infection * No major organ system dysfunction including, but not limited to, the following: * New York Heart Association class III or IV congestive heart failure * Pulmonary disease requiring the use of inhaled steroids or bronchodilators * Renal, hepatic, gastrointestinal, neurologic, or psychiatric dysfunction that would impair ability to participate in the study PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior hematopoietic stem cell transplantation * At least 3 weeks since prior corticosteroids (i.e., glucocorticoids) * At least 3 weeks since prior myeloma-specific therapy * At least 4 weeks since participation in any clinical trial that involved an investigational drug or device * No concurrent therapy with any of the following: * Corticosteroids (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone \[Decadron\]) * Inhaled steroids used for treatment of allergic rhinitis or pulmonary disease allowed * Thalidomide * Interferon * Growth factors, interleukins, or other cytokines (except filgrastim \[G-CSF\] as outlined in the protocol, or erythropoietin) * Cytotoxic chemotherapy agents (except cyclophosphamide for stem cell mobilization and high-dose melphalan) * Immunosuppressive drugs * Experimental therapies * Radiotherapy
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m\^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.
intervention Names
Biological: MILs
Drug: Melphalan
Biological: PCV13
label
ASCT+MILs
type
EXPERIMENTAL

interventions

arm Group Labels
ASCT+MILs
name
MILs
other Names
Marrow infiltrating lymphocytes
Activated marrow infiltrating lymphocytes
aMILs
type
BIOLOGICAL
arm Group Labels
ASCT+MILs
name
Melphalan
other Names
Alkeran
type
DRUG
arm Group Labels
ASCT+MILs
name
PCV13
other Names
Prevnar
type
BIOLOGICAL

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 26
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Days to absolute neutrophil count \> 500 cells per microliter.
measure
Hematopoietic Engraftment
time Frame
Up to 1 year
description
Percentage of participants with partial or complete response by Bladé criteria. Partial response is defined as a \>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.
measure
Disease Response
time Frame
Up to 2 years
description
Success rate of expanding MILs in vitro and obtaining a protocol-specified product.
measure
Feasibility of MILs Generation as Assessed by Percentage of Participants With Successful MIL Generation
time Frame
Up to 1 year

secondary Outcomes

description
ALC counts trending over time.
measure
T-cell Reconstitution as Determined by Absolute Lymphocyte Count (ALC)
time Frame
Days 14, 28, 60, 180, and 360
description
Survival in months for participants who are alive (Overall Survival) and alive without disease progression (Progression-free survival). Disease progression is defined as a change from negative to positive on immunofixation or electrophoresis for participants previously in complete remission or a 25% increase in serum electrophoresis for participants not previously in complete remission. Partial response is defined as a \>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \< 5% plasma cells.
measure
Survival
time Frame
Up to 129 months
description
CRM-197 Prevnar-specific vaccine responses that measure the T-cell response of the vaccine quantified as %CD3+/CFSE-low/IFN-gamma+.
measure
Pneumococcal-specific Vaccine Responses
time Frame
At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant
description
Myeloma lysate response that measures the T-cell response quantified as %CD3+/CFSE-low/IFN-gamma+.
measure
Anti-tumor Immune Responses
time Frame
At time of bone marrow harvest, Day 60 post-transplant, Day 180 post-transplant, and Day 360 post-transplant

Full study description

brief Summary: RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body. This may be an effective treatment for patients undergoing a stem cell transplant for multiple myeloma. PURPOSE: This phase I/II trial is studying the side effects of activated white blood cells and to see how well they work in treating patients who are undergoing a stem cell transplant for newly diagnosed stage II or stage III multiple myeloma.
detailed Description: OBJECTIVES: Primary * Evaluate the safety and response rate of activated marrow infiltrating lymphocytes (aMILs) in patients undergoing autologous peripheral blood stem cell transplantation for newly diagnosed, stage II-III multiple myeloma. * Determine the overall in vitro fold-expansion and assess pre- and post-expansion for myeloma T-cell specificity in assessing the feasibility of generating aMILs from myeloma patients. * Assess the toxicity of aMILs. * Evaluate the effect of aMILs on hematopoietic engraftment, including neutrophil engraftment, platelet engraftment, and primary graft failure (if failure occurs). * Evaluate response rates utilizing the Blade criteria, including the complete response (CR) rate, near complete response (nCR) rate, very good partial response (VGPR) rate, partial response (PR) rate, minimal response (MR) rate, and overall response rate (CR, VGPR, PR, MR). Secondary * Evaluate T-cell reconstitution, including absolute lymphocyte counts, CD3+, CD4+, and CD8+ T-cell counts. * Evaluate progression-free survival and overall survival. * Evaluate anti-tumor immune response. * Determine pneumococcal-specific vaccine responses. * Determine delayed-type hypersensitivity (DTH) responses. OUTLINE: Patients undergo collection of marrow infiltrating lymphocytes (MILs)\* either at diagnosis prior to the initiation of induction therapy or upon completion of induction therapy. The MILs bone marrow product undergo ex vivo activation and expansion of T cells for 7-8 days to produce activated marrow infiltrating lymphocytes (aMILs). Patients then undergo stem cell mobilization and leukapheresis to collect the peripheral blood stem cells 12 days after mobilization. Patients receive melphalan IV over 20-30 minutes on days -2 and -1 and undergo a peripheral blood stem cell transplantation on day 0 as planned. Patients receive aMILs infusion on day 3. Patients receive pneumococcal polyvalent vaccine on day 21. NOTE: \*Patients who have completed induction therapy receive pneumococcal polyvalent vaccine approximately 2 weeks prior to MILs collection; patients undergoing MILs collection prior to starting induction therapy do not receive a pre-transplantation vaccine. Blood and bone marrow samples are collected periodically for laboratory correlative studies. After completion of study treatment, patients are followed periodically for up to 1 year.

Source references

references

citation
Noonan KA, Huff CA, Davis J, Lemas MV, Fiorino S, Bitzan J, Ferguson A, Emerling A, Luznik L, Matsui W, Powell J, Fuchs E, Rosner GL, Epstein C, Rudraraju L, Ambinder RF, Jones RJ, Pardoll D, Borrello I. Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 May 20;7(288):288ra78. doi: 10.1126/scitranslmed.aaa7014.
pmid
25995224
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-7f8eaf2e7d617fe40476
requested nct id
NCT00566098
primary nct id
NCT00566098
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
f19aba4b57cbd72a18bdf37fa21d74935171c25c50efba9ab47f49b6f3c3aa03
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-7f8eaf2e7d617fe40476
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00566098
occurrences
context exact
NCT00566098
end
11
exact text
NCT00566098
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/355/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
3f9ef1a623b3af30cfe5a98801567baeefae96a5c92c30bbc62d0feec3586aaf
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice